EGFR and head and neck squamous cell carcinoma: As the treatment advances, there were several novel agents developed for R/M HNSCC, including an anti-epidermal growth factor receptor antibody, cetuximab, and an anti-programmed death-1 immune checkpoint inhibitor, pembrolizumab and nivolumab.